|
시장보고서
상품코드
2054999
요실금 치료 시장 : 약물 종류별, 요실금 유형별, 투여 경로별, 성별, 연령층별, 약물 유형별, 최종사용자별, 유통 채널별, 지역별Urinary Incontinence Therapeutics Market, By Drug Class, By Incontinence Type, By Route of Administration, By Gender, By Age Group, By Drug Type, By End User, By Distribution Channel, By Geography |
||||||
요실금 치료 시장은 2026년에 49억 달러로 추정되며, 2033년에 67억 6,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 4.7%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 49억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026-2033년까지 예측 기간 CAGR: | 4.70% | 2033년 시장 규모 예측: | 67억 6,000만 달러 |
전 세계 요실금 치료 시장은 광범위한 헬스케어 산업에서 중요한 분야로, 전 세계 수백만 명에게 영향을 미치고 있음에도 불구하고 보고가 부족한 가장 흔한 질환 중 하나를 다루고 있습니다. 요실금은 의도치 않게 방광 조절 능력을 상실하는 것이 특징이며, 다양한 연령층에 영향을 미치지만, 해부학적 및 생리학적 요인으로 인해 주로 고령자나 여성에게서 많이 나타납니다. 이러한 증상에는 복압성 요실금, 절박성 요실금, 과다배출성 요실금, 혼합성 요실금 등 여러 유형이 있으며, 각각 다른 치료 접근법이 필요합니다.
이 시장에는 항콜린제, β-3 작용제, α-차단제 등의 약물 요법뿐만 아니라, 의료기기, 외과적 시술, 행동 요법 등의 비약물 요법을 포함한 종합적인 치료법이 모두 포함되어 있습니다. 의료 기술의 발전, 혁신적인 의약품 제제, 그리고 최소침습 치료법의 등장으로 치료 방식은 끊임없이 진화하고 있습니다. 의료 종사자들은 요실금이 환자의 삶의 질, 사회적 교류, 심리적 안녕에 미치는 중대한 영향을 점점 더 인식하고 있으며, 이는 효과적인 치료 솔루션에 대한 수요를 이끌고 있습니다. 이 시장의 성장은 건강에 대한 인식 제고, 진단 능력 향상, 치료를 받는 것에 대한 편견 감소, 신흥국의 의료 인프라 확충에 힘입어 더욱 가속화되고 있으며, 이 시장은 현대 의료 제공 시스템에서 없어서는 안 될 요소로서의 입지를 확고히 하고 있습니다.
시장 역학
전 세계 요실금 치료 시장은 그 성장세를 종합적으로 뒷받침하는 몇 가지 강력한 요인에 의해 주로 견인되고 있습니다. 고령화가 진행되고 있는 세계 인구는 가장 중요한 성장 요인이 되고 있습니다. 고령화는 골반저근의 약화, 호르몬 변화, 동반 질환으로 인해 요실금 발생률 증가와 밀접한 관련이 있기 때문입니다. 당뇨병, 비만, 신경 질환의 유병률 증가 또한 시장 수요를 더욱 확대시키고 있습니다. 이러한 질환들은 요실금 발병 위험을 현저히 높이기 때문입니다. 의료 기관 및 환자 지원 단체의 인식 제고 활동이 확대됨에 따라 사회적 금기를 깨고 더 많은 사람이 의료적 개입을 요청하도록 유도하고 있으며, 이에 따라 대상 환자층이 크게 확대되고 있습니다.
약물전달 시스템의 기술적 진보, 효능이 향상된 신약의 개발, 그리고 최소침습 수술의 도입으로 인해 환자와 의료진 모두에게 매력적인 새로운 치료 패러다임이 등장하고 있습니다. 그러나 시장에는 뚜렷한 억제요인도 존재합니다. 특히 배뇨 조절 문제에 대해 이야기하는 것이 여전히 문화적으로 민감한 보수적인 사회에서는 뿌리 깊은 사회적 편견이 많은 환자의 진료 받기를 방해하고 있습니다. 많은 지역에서 높은 치료비와 제한적인 보험 적용 범위는, 특히 장기적인 치료 계획의 경우, 의료 서비스 이용을 가로막는 큰 장벽이 되고 있습니다. 게다가 항콜린제에 의한 구강 건조, 변비, 인지 기능 장애 등 약물 치료에 수반되는 잠재적인 부작용이 환자의 복약 순응도와 치료 수용도를 저해하고 있습니다.
이러한 과제가 있음에도 불구하고, 의료 인프라의 개선으로 전문적인 비뇨기과 의료 서비스에 대한 접근성이 확대되고 있는 개발도상국의 미개척 시장을 통해 큰 기회가 창출되고 있습니다. 디지털 헬스 기술, 원격의료 플랫폼, 원격 모니터링 시스템의 통합은 환자 관리 및 치료 순응도를 위한 혁신적인 방향을 제시하고 있습니다. 또한, 맞춤형 의료 접근법, 바이오마커의 규명, 새로운 치료 표적에 대한 지속적인 연구는 치료 효과에 혁명을 일으키고 새로운 시장 부문을 창출할 것으로 기대됩니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 요실금 치료 시장의 주요 기업 개요을 작성했습니다. 구체적으로는 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략입니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 요실금 치료 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 요실금 치료 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 요실금 치료 시장 : 약물 종류별, 2021-2033년
제5장 세계의 요실금 치료 시장 : 요실금 유형별, 2021-2033년
제6장 세계의 요실금 치료 시장 : 투여 경로별, 2021-2033년
제7장 세계의 요실금 치료 시장 : 성별, 2021-2033년
제8장 세계의 요실금 치료 시장 : 연령층별, 2021-2033년
제9장 세계의 요실금 치료 시장 : 약물 유형별, 2021-2033년
제10장 세계의 요실금 치료 시장 : 최종사용자별, 2021-2033년
제11장 세계의 요실금 치료 시장 : 유통 채널별, 2021-2033년
제12장 세계의 요실금 치료 시장 : 지역별, 2021-2033년
제13장 경쟁 구도
제14장 애널리스트의 제안
제15장 참고문헌과 조사 방법
KSM 26.06.18Urinary Incontinence Therapeutics Market is estimated to be valued at USD 4.90 Bn in 2026 and is expected to reach USD 6.76 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.90 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.70% | 2033 Value Projection: | USD 6.76 Bn |
The global urinary incontinence therapeutics market represents a critical segment within the broader healthcare industry, addressing one of the most prevalent yet underreported medical conditions affecting millions worldwide. Urinary incontinence, characterized by the involuntary loss of bladder control, impacts individuals across various age groups but predominantly affects elderly populations and women due to anatomical and physiological factors. This condition encompasses multiple types including stress incontinence, urge incontinence, overflow incontinence, and mixed incontinence, each requiring distinct therapeutic approaches.
The market encompasses a comprehensive range of treatment modalities including pharmacological interventions such as anticholinergics, beta-3 agonists, and alpha-blockers, alongside non-pharmacological solutions including medical devices, surgical procedures, and behavioral therapies. The therapeutic landscape continues to evolve with advancing medical technologies, innovative drug formulations, and minimally invasive treatment options. Healthcare providers increasingly recognize the significant impact of urinary incontinence on patients' quality of life, social interactions, and psychological well-being, driving demand for effective therapeutic solutions. The market growth is further propelled by rising healthcare awareness, improved diagnostic capabilities, reduced stigma associated with seeking treatment, and expanding healthcare infrastructure in emerging economies, positioning this market as a vital component of modern healthcare delivery systems.
Market Dynamics
The global urinary incontinence therapeutics market is primarily driven by several compelling factors that collectively fuel its expansion trajectory. The aging global population serves as the most significant growth driver, as advanced age correlates strongly with increased incidence of urinary incontinence due to weakened pelvic floor muscles, hormonal changes, and comorbid conditions. Rising prevalence of diabetes, obesity, and neurological disorders further amplifies market demand, as these conditions significantly increase the risk of developing incontinence. Growing awareness campaigns by healthcare organizations and patient advocacy groups are breaking down social taboos and encouraging more individuals to seek medical intervention, substantially expanding the addressable patient population.
Technological advancements in drug delivery systems, development of novel pharmacological agents with improved efficacy profiles, and introduction of minimally invasive surgical procedures are creating new treatment paradigms that attract both patients and healthcare providers. However, the market faces notable restraints including persistent social stigma that prevents many patients from seeking treatment, particularly in conservative societies where discussing bladder control issues remains culturally sensitive. High treatment costs and limited insurance coverage in many regions create significant barriers to access, especially for long-term therapeutic regimens. Additionally, potential side effects associated with pharmacological treatments, such as dry mouth, constipation, and cognitive impairment from anticholinergic medications, limit patient compliance and treatment adoption.
Despite these challenges, substantial opportunities emerge through untapped markets in developing countries where healthcare infrastructure improvements are expanding access to specialized urological care. The integration of digital health technologies, telemedicine platforms, and remote monitoring systems presents innovative avenues for patient management and treatment adherence. Furthermore, ongoing research into personalized medicine approaches, biomarker identification, and novel therapeutic targets promises to revolutionize treatment effectiveness and create new market segments.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global urinary incontinence therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Astellas Pharma, Pfizer, AbbVie, Merck, Allergan, Teva Pharmaceutical, Janssen, Dr. Reddy's Laboratories, Endo Pharmaceuticals, Sumitomo Pharma, Mylan, Eli Lilly, Takeda, Sanofi, and GlaxoSmithKline
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global urinary incontinence therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary incontinence therapeutics market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Muscarinic Receptor Antagonists (Anticholinergics)
- Solifenacin
- Fesoterodine
- Oxybutynin
- Darifenacin
- Tolterodine
- Trospium
- βa,f-Adrenergic Receptor Agonists
- Mirabegron
- Vibegron
- Combination Therapy
- Mirabegron + Solifenacin
- Neurotoxin/Neuromuscular Blocker
- OnabotulinumtoxinA
- Other Late Phase Drugs
- Incontinence Type Insights (Revenue, USD Bn, 2021 - 2033)
- Urge/Overactive Bladder (OAB)/Urge Urinary Incontinence (UUI)
- Stress Urinary Incontinence (SUI)
- Mixed Urinary Incontinence (SUI + UUI)
- Overflow Urinary Incontinence
- Functional incontinence
- Other (Neurogenic/Detrusor Overactivity)
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Intravesical/bladder instillation
- Topical
- Injectable/intradetrusor
- Gender Insights (Revenue, USD Bn, 2021 - 2033)
- Male
- Female
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adult (19-64 years)
- Pediatric (≤18 years)
- Geriatric (≥65 years)
- Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
- Brand
- Generic
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty/Urology clinics
- Ambulatory surgical centers
- Home care/outpatient use
- Long-term care facilities
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Astellas Pharma
- Pfizer
- AbbVie
- Merck
- Allergan
- Teva Pharmaceutical
- Janssen
- Reddy's Laboratories
- Endo Pharmaceuticals
- Sumitomo Pharma
- Mylan
- Eli Lilly
- Takeda
- Sanofi
- GlaxoSmithKline
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Urinary Incontinence Therapeutics Market, By Drug Class
- Global Urinary Incontinence Therapeutics Market, By Incontinence Type
- Global Urinary Incontinence Therapeutics Market, By Route of Administration
- Global Urinary Incontinence Therapeutics Market, By Gender
- Global Urinary Incontinence Therapeutics Market, By Age Group
- Global Urinary Incontinence Therapeutics Market, By Drug Type
- Global Urinary Incontinence Therapeutics Market, By End User
- Global Urinary Incontinence Therapeutics Market, By Distribution Channel
- Global Urinary Incontinence Therapeutics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Urinary Incontinence Therapeutics Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Muscarinic Receptor Antagonists (Anticholinergics)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Solifenacin
- Fesoterodine
- Oxybutynin
- Darifenacin
- Tolterodine
- Trospium
- βa,f-Adrenergic Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Mirabegron
- Vibegron
- Combination Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Mirabegron + Solifenacin
- Neurotoxin/Neuromuscular Blocker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- OnabotulinumtoxinA
- Other Late Phase Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Urinary Incontinence Therapeutics Market, By Incontinence Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Urge/Overactive Bladder (OAB)/Urge Urinary Incontinence (UUI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Stress Urinary Incontinence (SUI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Mixed Urinary Incontinence (SUI + UUI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Overflow Urinary Incontinence
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Functional incontinence
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other (Neurogenic/Detrusor Overactivity)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Urinary Incontinence Therapeutics Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intravesical/bladder instillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Injectable/intradetrusor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Urinary Incontinence Therapeutics Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Urinary Incontinence Therapeutics Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adult (19-64 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pediatric (≤18 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric (≥65 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Urinary Incontinence Therapeutics Market, By Drug Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Urinary Incontinence Therapeutics Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty/Urology clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory surgical centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Home care/outpatient use
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Long-term care facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Urinary Incontinence Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
12. Global Urinary Incontinence Therapeutics Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Endo Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumitomo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
